METTL24

Across TCGA pan-cancer cohorts, METTL24 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated METTL24 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher METTL24 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL24 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, COAD, and SKCM are the cancer types where METTL24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
COAD	DFS	Median	All	0.158	0.501	.042	3	view →
SKCM	DFS	Median	III,IV	1.000	0.601	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

METTL24–STAD (OS)

Open the STAD breakdown →